| scholarly article | Q13442814 |
| P356 | DOI | 10.1056/NEJM200011023431801 |
| P698 | PubMed publication ID | 11058672 |
| P2093 | author name string | F G Hayden | |
| L V Gubareva | |||
| S J Sharp | |||
| J M Hammond | |||
| M J Elliot | |||
| A S Monto | |||
| M J Ossi | |||
| T C Klein | |||
| Zanamivir Family Study Group | |||
| P433 | issue | 18 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | zanamivir | Q146075 |
| P304 | page(s) | 1282-1289 | |
| P577 | publication date | 2000-11-01 | |
| P1433 | published in | The New England Journal of Medicine | Q582728 |
| P1476 | title | Inhaled zanamivir for the prevention of influenza in families. Zanamivir Family Study Group | |
| P478 | volume | 343 |
| Q31171693 | A Data-Augmentation Method for Infectious Disease Incidence Data from Close Contact Groups |
| Q30351398 | A new European perspective of influenza pandemic planning with a particular focus on the role of mammalian cell culture vaccines. |
| Q35612523 | A new millennium conundrum: how to use a powerful class of influenza anti-neuraminidase drugs (NAIs) in the community |
| Q56908839 | A primer on strategies for prevention and control of seasonal and pandemic influenza |
| Q34419159 | Adverse cutaneous reactions to influenza vaccinations and chemotherapy |
| Q35685188 | Aerosolized cidofovir is retained in the respiratory tract and protects mice against intranasal cowpox virus challenge |
| Q24187883 | Amantadine and rimantadine for influenza A in children and the elderly |
| Q24203853 | Amantadine and rimantadine for influenza A in children and the elderly |
| Q24242639 | Amantadine and rimantadine for influenza A in children and the elderly |
| Q35564316 | An update on the prevention of influenza in children and adolescents |
| Q34714853 | Animal Models for Influenza Virus Pathogenesis and Transmission |
| Q34556303 | Anti-influenza therapies. |
| Q93238882 | Antiviral agents against respiratory viruses |
| Q43759388 | Antiviral drugs with extra-cellular sites of action |
| Q30358735 | Antiviral management of seasonal and pandemic influenza. |
| Q53766773 | Antivirals for influenza in healthy adults. |
| Q30393095 | Antivirals for influenza: strategies for use in pediatrics |
| Q30401837 | Assessing secondary attack rates among household contacts at the beginning of the influenza A (H1N1) pandemic in Ontario, Canada, April-June 2009: a prospective, observational study |
| Q64134362 | Clinical Practice Guidelines by the Infectious Diseases Society of America: 2018 Update on Diagnosis, Treatment, Chemoprophylaxis, and Institutional Outbreak Management of Seasonal Influenzaa |
| Q38367260 | Clinical pharmacokinetics of inhaled antimicrobials. |
| Q28272841 | Clinical pharmacokinetics of laninamivir, a novel long-acting neuraminidase inhibitor, after single and multiple inhaled doses of its prodrug, CS-8958, in healthy male volunteers |
| Q41932743 | Commentary: A Historical Review of Centers for Disease Control and Prevention Antiviral Treatment and Postexposure Chemoprophylaxis Guidance for Human Infections With Novel Influenza A Viruses Associated With Severe Human Disease |
| Q37087135 | Communicability of H1N1 and seasonal influenza among household contacts of cases in large families |
| Q28364114 | Comparison of the activities of zanamivir, oseltamivir, and RWJ-270201 against clinical isolates of influenza virus and neuraminidase inhibitor-resistant variants |
| Q36777840 | Current non-AIDS antiviral chemotherapy |
| Q44119551 | Current strategies for management of influenza in the elderly population |
| Q51699647 | Delays in the application of outbreak control prophylaxis for influenza A in a nursing home. |
| Q34211412 | Design and Evaluation of Prophylactic Interventions Using Infectious Disease Incidence Data from Close Contact Groups |
| Q30308218 | Detection of influenza virus resistance to neuraminidase inhibitors by an enzyme inhibition assay |
| Q42686662 | Disruption of services in an internal medicine unit due to a nosocomial influenza outbreak |
| Q74227037 | Drug resistance and influenza pandemics |
| Q43173004 | Dynamic epidemic model for influenza with clinical complications |
| Q30371134 | Economic evaluation of influenza pandemic mitigation strategies in the United States using a stochastic microsimulation transmission model. |
| Q36020202 | Economic evaluations of neuraminidase inhibitors to control influenza |
| Q40264783 | Effects of oseltamivir treatment of index patients with influenza on secondary household illness in an urban setting in Bangladesh: secondary analysis of a randomised, placebo-controlled trial |
| Q24530163 | Entry of parainfluenza virus into cells as a target for interrupting childhood respiratory disease |
| Q33559473 | Epidemiology and potential preventative measures for viral infections in children with malignancy and those undergoing hematopoietic cell transplantation |
| Q30373782 | Estimating antiviral effectiveness against pandemic influenza using household data |
| Q24536333 | Existing antivirals are effective against influenza viruses with genes from the 1918 pandemic virus. |
| Q26858861 | Household transmission of 2009 pandemic influenza A (H1N1): a systematic review and meta-analysis |
| Q30387397 | Household transmission of pandemic (H1N1) 2009, San Antonio, Texas, USA, April-May 2009. |
| Q29619174 | In vitro and in vivo characterization of new swine-origin H1N1 influenza viruses |
| Q34045479 | In vitro system for modeling influenza A virus resistance under drug pressure |
| Q34058480 | Incidence of influenza in healthy adults and healthcare workers: a systematic review and meta-analysis |
| Q35972890 | Infectious triggers of asthma |
| Q57116936 | Influenza |
| Q73495234 | Influenza |
| Q30396017 | Influenza A (H1N1) in Victoria, Australia: a community case series and analysis of household transmission |
| Q35546249 | Influenza Therapy |
| Q30404293 | Influenza and HIV: lessons from the 2009 H1N1 influenza pandemic |
| Q30309203 | Influenza in the acute hospital setting |
| Q35800321 | Influenza in the intensive care unit |
| Q37857854 | Influenza pharmacotherapy: present situation, strategies and hopes |
| Q30353587 | Influenza testing, diagnosis, and treatment in the emergency department in 2009-2010 and 2010-2011 |
| Q35005570 | Influenza transmission in a cohort of households with children: 2010-2011 |
| Q35063671 | Influenza vaccination and antiviral therapy: is there a role for concurrent administration in the institutionalised elderly? |
| Q34991460 | Influenza vaccinations: who needs them and when? |
| Q40579386 | Influenza virus infection in adult solid organ transplant recipients |
| Q33701528 | Influenza virus resistance to antiviral agents: a plea for rational use. |
| Q40373841 | Informed patient consent to participation in cluster randomized trials: an empirical exploration of trials in primary care. |
| Q26822988 | Inhaled anti-infective chemotherapy for respiratory tract infections: successes, challenges and the road ahead |
| Q30445615 | Kinetics of influenza A virus infection in humans |
| Q37083473 | Laninamivir octanoate for post-exposure prophylaxis of influenza in household contacts: a randomized double blind placebo controlled trial |
| Q36090658 | Management of influenza virus infections with neuraminidase inhibitors: detection, incidence, and implications of drug resistance |
| Q91901453 | Microstructure of atmospheric particles revealed by TXM and a new mode of influenza virus transmission |
| Q30359861 | Neuraminidase inhibitors and risk of H5N1 influenza |
| Q24203875 | Neuraminidase inhibitors for preventing and treating influenza in children |
| Q24243136 | Neuraminidase inhibitors for preventing and treating influenza in children |
| Q24247957 | Neuraminidase inhibitors for preventing and treating influenza in children |
| Q24200222 | Neuraminidase inhibitors for preventing and treating influenza in children (published trials only) |
| Q24240097 | Neuraminidase inhibitors for preventing and treating influenza in healthy adults |
| Q24244898 | Neuraminidase inhibitors for preventing and treating influenza in healthy adults |
| Q24203905 | Neuraminidase inhibitors for preventing and treating influenza in healthy adults and children |
| Q24644585 | Neuraminidase inhibitors for preventing and treating influenza in healthy adults: systematic review and meta-analysis |
| Q35045959 | Neuraminidase inhibitors in pediatric patients: potential place in influenza therapy |
| Q30452889 | Neuraminidase sequence analysis and susceptibilities of influenza virus clinical isolates to zanamivir and oseltamivir. |
| Q30332341 | New millennium antivirals against pandemic and epidemic influenza: the neuraminidase inhibitors. |
| Q34164493 | New treatments for viral respiratory tract infections--opportunities and problems |
| Q35230743 | Optimal design of studies of influenza transmission in households. I: case-ascertained studies. |
| Q37445706 | Optimal design of studies of influenza transmission in households. II: comparison between cohort and case-ascertained studies |
| Q36593645 | Oseltamivir and inhaled zanamivir as influenza prophylaxis in Thai health workers: a randomized, double-blind, placebo-controlled safety trial over 16 weeks |
| Q45036677 | Oseltamivir-resistant influenza? |
| Q30233416 | Pandemic Influenza and Healthcare Demand in the Netherlands: Scenario Analysis |
| Q30353151 | Pandemics, avian influenza A (H5N1), and a strategy for pharmacists. |
| Q24522384 | Perspectives on antiviral use during pandemic influenza |
| Q30450742 | Phenotypic drug susceptibility assay for influenza virus neuraminidase inhibitors |
| Q24675532 | Pneumococcal and influenza vaccination: current situation and future prospects |
| Q34341199 | Pneumonia in pregnancy |
| Q30353815 | Post-exposure influenza prophylaxis with oseltamivir: cost effectiveness and cost utility in families in the UK. |
| Q37204154 | Prediction of the pharmacodynamically linked variable of oseltamivir carboxylate for influenza A virus using an in vitro hollow-fiber infection model system |
| Q37147720 | Prevention of influenza in healthy children |
| Q35943670 | Prevention of influenza in the general population |
| Q57569167 | Probiotic bacteria reduced duration and severity but not the incidence of common cold episodes in a double blind, randomized, controlled trial |
| Q31992333 | Prophylactic and symptomatic treatment of influenza. Current and developing options |
| Q36630470 | Protecting pediatric oncology patients from influenza |
| Q35740698 | Pulmonary complications of solid organ and hematopoietic stem cell transplantation |
| Q43071563 | Questioning aerosol transmission of influenza |
| Q40763384 | Rapid and sensitive detection of respiratory virus infections for directed antiviral treatment using R-Mix cultures |
| Q30390080 | Recommendations for the prevention and treatment of influenza using antiviral drugs based on cost-effectiveness |
| Q37496797 | Reducing the burden of influenza-associated complications with antiviral therapy |
| Q36145000 | Reducing the impact of viral respiratory infections in children |
| Q34575342 | Relationship of viral infections to wheezing illnesses and asthma |
| Q36937327 | Restoring invisible and abandoned trials: a call for people to publish the findings |
| Q29619563 | Review of aerosol transmission of influenza A virus |
| Q38149216 | Review of the clinical effectiveness of the neuraminidase inhibitors against influenza B viruses. |
| Q34249434 | Risk factors of influenza transmission in households |
| Q35152279 | Safety and immunoenhancing effect of a Chlorella-derived dietary supplement in healthy adults undergoing influenza vaccination: randomized, double-blind, placebo-controlled trial |
| Q30419114 | Seasonal and pandemic influenza: an overview with pediatric focus |
| Q48585293 | Seasonal influenza in adults and children--diagnosis, treatment, chemoprophylaxis, and institutional outbreak management: clinical practice guidelines of the Infectious Diseases Society of America |
| Q37186906 | Seasonal influenza in the United States, France, and Australia: transmission and prospects for control |
| Q30418073 | Secondary household transmission of 2009 pandemic influenza A (H1N1) virus among an urban and rural population in Kenya, 2009-2010 |
| Q35627901 | Spotlight on zanamivir in influenza |
| Q40331320 | Stockpile, use during outbreaks, restock, repeat |
| Q43545011 | Susceptibility of recent Canadian influenza A and B virus isolates to different neuraminidase inhibitors |
| Q21261835 | Systematic review of influenza resistance to the neuraminidase inhibitors |
| Q43245235 | Tackling the next influenza pandemic |
| Q34169126 | The common cold |
| Q30341652 | The expected number of hospitalisations and beds needed due to pandemic influenza on a regional level in the Netherlands. |
| Q37292575 | The impact of influenza on working days lost: a review of the literature |
| Q36790658 | The threat of avian influenza A (H5N1). Part III: Antiviral therapy. |
| Q36171279 | The use of antiviral drugs for influenza: recommended guidelines for practitioners |
| Q43890868 | The use of zanamivir to treat influenza A and B infection after allogeneic stem cell transplantation |
| Q21090775 | The value of neuraminidase inhibitors for the prevention and treatment of seasonal influenza: a systematic review of systematic reviews |
| Q37975932 | Therapeutics against influenza |
| Q43485506 | Treatment of aerosolized cowpox virus infection in mice with aerosolized cidofovir |
| Q30332727 | Treatment of epidemic and pandemic influenza with neuraminidase and M2 proton channel inhibitors |
| Q36411968 | Treatment of respiratory virus infections |
| Q21559446 | Use of neuraminidase inhibitors for rapid containment of influenza: a systematic review and meta-analysis of individual and household transmission studies |
| Q43975411 | Use of oseltamivir during influenza outbreaks in Ontario nursing homes, 1999-2000. |
| Q36385284 | Vaccine-associated reduction in symptom severity among patients with influenza A/H3N2 disease |
| Q36167370 | Viral respiratory infections in cystic fibrosis |
| Q38304332 | Virus-induced modulation of lower airway diseases: pathogenesis and pharmacologic approaches to treatment |
| Q30329986 | World War I may have allowed the emergence of "Spanish" influenza. |
| Q34229084 | Zanamivir and oseltamivir: two new options for the treatment and prevention of influenza |
| Q37167230 | Zanamivir for the prevention of influenza in adults and children age 5 years and older. |
| Q30398935 | Zanamivir, at 600 milligrams twice daily, inhibits oseltamivir-resistant 2009 pandemic H1N1 influenza virus in an in vitro hollow-fiber infection model system |
| Q34481313 | Zanamivir: a review of clinical safety in individuals at high risk of developing influenza-related complications |
| Q40419399 | Zanamivir: an influenza virus neuraminidase inhibitor |
| Q34492611 | Zanamivir: an update of its use in influenza |
| Q28344586 | Zanamivir: from drug design to the clinic |
| Q73978014 | [Antiviral agents in the treatment of influenza] |
Search more.